75000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)(Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - Organization
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995475 - Disclosure - Financial Instruments
link:presentationLink
link:calculationLink
link:definitionLink
995485 - Disclosure - Balance Sheet Components
link:presentationLink
link:calculationLink
link:definitionLink
995495 - Disclosure - Revenue
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - Investment in Amlogenyx. Inc.
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - License and Research Agreements
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - Liabilities for Sales of Future Royalties
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - Stock-Based Awards
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - Net Loss Per Share
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - Equity
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - Related Party Transaction
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - Accumulated Other Comprehensive Loss
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - Strategic Restructuring Plan
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - Subsequent Events
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - Summary of Significant Accounting Policies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995625 - Disclosure - Financial Instruments (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - Balance Sheet Components (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - Revenue (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995655 - Disclosure - Investment in Amlogenyx Inc. (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - License and Research Agreements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - Liabilities for Sales of Future Royalties (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - Stock-Based Awards (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - Net Loss Per Share (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - Accumulated Other Comprehensive Loss (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995715 - Disclosure - Strategic Restructuring Plan (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995725 - Disclosure - Organization - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995735 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - Financial Instruments - Summary of Financial Assets Measured on Recurring Basis (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Balance Sheet Components - Summary of Cash Equivalents and Marketable Securities Classified as Available For Sale Securities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - Balance Sheet Components - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - Balance Sheet Components - Summary of Inventory (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995805 - Disclosure - Revenue - Summary of Disaggregation of Total Revenues from Customers (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - Revenue - Summary of Disaggregation of Total Revenues (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - Revenue - Summary of Changes in Contract Liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - Revenue - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Investment in Amlogenyx Inc. - Changes in the Carrying Value of Noncontrolling Interest (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - Investment in Amlogenyx Inc. - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - License and Research Agreements - Kyowa Kirin Co., Ltd. - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995875 - Disclosure - License and Research Agreements - Regeneron - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995885 - Disclosure - License and Research Agreements - GeneTx Biotherapeutics LLC - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995895 - Disclosure - License and Research Agreements - Mereo - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995905 - Disclosure - License and Research Agreements - Share of Collaboration and Royalty Revenue Related to Crysvita (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995915 - Disclosure - License and Research Agreements - Schedule of Cost Sharing Payments (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995925 - Disclosure - License and Research Agreements - Schedule of Changes in Fair Value of Equity Investment (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995935 - Disclosure - Liabilities for Sales of Future Royalties - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995945 - Disclosure - Liabilities for Sales of Future Royalties - Schedule of Key Terms and Activity of Sales of Future Royalties (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995955 - Disclosure - Liabilities for Sales of Future Royalties - Schedule of Key Terms and Activity of Sales of Future Royalties - (Parenthetical) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995965 - Disclosure - Liabilities for Sales of Future Royalties - Schedule of Activity Within Liability Related to Sale of Future Royalties (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995975 - Disclosure - Stock-Based Awards - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995985 - Disclosure - Stock-Based Awards - Summary of Stock-Based Compensation Expense (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995995 - Disclosure - Net Loss Per Share - Outstanding Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996005 - Disclosure - Equity - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996015 - Disclosure - Related Party Transaction - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996025 - Disclosure - Accumulated Other Comprehensive Loss - Schedule of Total Accumulated Other Comprehensive Loss (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996035 - Disclosure - Strategic Restructuring Plan - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996045 - Disclosure - Strategic Restructuring Plan - Summary of restructuring charges and amounts paid or settled (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996055 - Disclosure - Strategic Restructuring Plan - Summary of total restructuring charges recognized on the condensed consolidated statements of operations (Details)
link:presentationLink
link:calculationLink
link:definitionLink
Restructuring Reserve
Restructuring Reserve, Total
Balance as of December 31, 2025
Balance as of June 30, 2026
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Balance Sheet Location
Statement of Financial Position Location, Balance [Domain]
Profit Share Revenue
Profit Share Revenue And Royalties [Member]
Profit share revenue and royalties.
Plan Name
Plan Name [Axis]
Equity [Abstract]
Entity Current Reporting Status
Entity Current Reporting Status
Texas A&M University [Member]
Texas A&M University [Member]
Texas AM University [Member]
Operating expenses:
Operating Expenses [Abstract]
Fair Value, Inputs, Level 2 [Member]
Level 2
Common stock, shares authorized
Common Stock, Shares Authorized
Accounts Receivable, after Allowance for Credit Loss, Total
License agreement accounts receivable
Accounts Receivable, after Allowance for Credit Loss
Product and Service
Product and Service [Axis]
Document Fiscal Period Focus
Document Fiscal Period Focus
Total revenues
Revenue from Contract with Customer [Abstract]
Entity Shell Company
Entity Shell Company
Schedule of activity within liability for sale of future royalties.
Schedule Of Activity Within Liability For Sale Of Future Royalties [Table Text Block]
Schedule of Activity Within Liability for Sale of Future Royalties
Other
Other Accrued Liabilities, Current
Segment Reporting, Policy [Policy Text Block]
Segment Reporting
Cash and Cash Equivalents, at Carrying Value, Ending Balance
Cash and Cash Equivalents, at Carrying Value, Beginning Balance
Cash and Cash Equivalents, at Carrying Value, Total
Cash and cash equivalents
Cash and Cash Equivalent
Pre Funded Warrant
Pre Funded Warrant [Member]
Pre Funded Warrant [Member]
Customer One.
Customer One [Member]
Customer One
Non-Rule 10b51 Arr Modified [Flag]
Non-rule 10b5-1 arrangement modified.
Non-Rule 10b5-1 Arrangement Modified
US And Canada
U.S. and Canada [Member]
U.S. and Canada.
Research and Development Arrangement, Contract to Perform for Others, Type
Research and Development Arrangement, Contract to Perform for Others, Type [Axis]
Common Stock, Shares, Issued, Total
Common stock, shares issued
Common Stock, Shares, Issued
Asset Class
Asset Class [Domain]
Statement [Table]
Statement [Table]
Restricted Cash, Noncurrent
Restricted cash included in other non-current assets
Latin America
Latin America [Member]
Royalty Repurchase Option Amount
Royalty Repurchase Option Amount.
Royalty repurchase amount
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax, Ending Balance
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax, Beginning Balance
Foreign currency translation adjustments
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax
Statement [Line Items]
Statement [Line Items]
Business Combination [Domain]
Entity Filer Category
Entity Filer Category
Liabilities and Equity
Total liabilities, noncontrolling interest and stockholders' deficit
Payables and Accruals [Abstract]
Restructuring Type [Axis]
Time Deposits
Time Deposits [Member]
Time deposits.
Financial Instruments
Financial Instruments Disclosure [Text Block]
Restructuring and Related Costs [Table Text Block]
Summary of Total restructuring charges recognized on the Condensed Consolidated Statements of Operations
Goodwill, Ending Balance
Goodwill, Beginning Balance
Goodwill, Total
Goodwill
Goodwill
Other
Other Noncash Income (Expense), Total
Other
Other Noncash Income (Expense)
Investment Income Interest, Total
Interest income
Investment Income, Interest
Debt Securities, Available-for-Sale, Noncurrent
Marketable securities
Geographical
Geographical [Domain]
Payment for intangible asset
Payments for intangible asset
Payments to Acquire Intangible Assets
Inventory, Finished Goods, Gross, Total
Finished goods
Inventory, Finished Goods, Gross
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]
Cash, Cash Equivalents and Restricted Cash
Asset-backed Securities
Asset-Backed Securities [Member]
Summary of Inventory
Schedule of Inventory, Current [Table Text Block]
Accounts Receivable, Allowance for Credit Loss
Accounts Receivable, Allowance for Credit Loss, Ending Balance
Accounts Receivable, Allowance for Credit Loss, Beginning Balance
Revenue related reserves
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
Non Cash interest expense on liability for sale of future royalties and capitalized to property plant and equipment.
Non Cash Interest Expense On Liability For Sale Of Future Royalties And Capitalized To Property Plant And Equipment
Non-cash interest expense
Deferred compensation assets.
Deferred Compensation Assets [Member]
Deferred Compensation Assets
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Stock options, granted
Disaggregation Of Revenue [Table]
Disaggregation of Revenue [Table]
Percentage of gross accounts receivable balance
Percentage Of Gross Accounts Receivable Balance
Percentage of gross accounts receivable balance.
Earnings Per Share, Basic, Total
Earnings Per Share, Basic
Net loss per share, basic
Summary of Disaggregation of Total Revenues
Disaggregation of Revenue [Table Text Block]
Total current liabilities
Liabilities, Current
Accounts receivable
Increase (Decrease) in Accounts Receivable
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]
Collaboration And License [Member]
Collaboration and license.
Collaboration and license
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent
Restructuring plan, workforce reduction percentage
Royalty Revenue for Sales in North American Territiory [Member]
Royalty revenue for sales in north american territory.
Royalty Revenue in North American Territory
Equity, Attributable to Parent [Abstract]
Stockholders' deficit:
Entity Small Business
Entity Small Business
Retained Earnings (Accumulated Deficit), Ending Balance
Retained Earnings (Accumulated Deficit), Beginning Balance
Retained Earnings (Accumulated Deficit), Total
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Theodore Huizenga [Member]
Theodore huizenga.
Theodore Huizenga [Member]
Organization
Nature of Operations [Text Block]
Other Current Assets [Member]
Other Current Assets
Stock-Based Awards
Share-Based Payment Arrangement [Text Block]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Commercial and Development Activity Reimbursements
Commercial And Development Activity Reimbursements [Member]
Commercial and development activity reimbursements.
Amendment Flag
Amendment Flag
Royalties transaction costs net
Royalties Transaction Costs Net
Royalties transaction costs net.
Product and Service
Product and Service [Domain]
Liabilities and Equity [Abstract]
Liabilities, Noncontrolling interest and Stockholders' Equity
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Net cash used in operating activities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description
Common Stock
Common Stock [Member]
Two Thousand Twenty Five OMERS Agreement [Member]
Two Thousand Twenty Five OMERS agreement.
2025 OMERS Agreement
Schedule Of Available For Sale Securities [Line Items]
Debt Securities, Available-for-Sale [Line Items]
Research and Development Arrangement, Contract to Perform for Others, Type
Research and Development Arrangement, Contract to Perform for Others, Type [Domain]
Series seed preferred stock [Member]
Series seed preferred stock.
Series Seed Preferred Stock [Member]
Effective annual interest rate
Debt Instrument, Interest Rate, Effective Percentage
Entity Address, Address Line One
Entity Address, Address Line One
Fair Value Hierarchy and NAV [Axis]
Issuance of common stock under equity plan awards, net of tax
Issuance Of Common Stock Under Equity Plan Awards Net Of Tax
Issuance of common stock under equity plan awards, net of tax.
Net income (loss) per share:
Earnings Per Share [Abstract]
Percentage of Royalties Sold
Percentage of royalties sold
Percentage of royalties sold.
Balance Sheet Location
Statement of Financial Position Location, Balance [Axis]
Investment Type
Investment Type [Axis]
Liabilities for Sales of Future Royalties
Liabilities for Sales of Future Royalties [Policy Text Block]
Liabilities for Sales of Future Royalties [Policy Text Block]
Non Profit Foundation [Member]
Non Profit Foundation [Member]
Non Profit Foundation [Member]
Payments to Acquire Debt Securities, Available-for-Sale
Purchase of marketable securities
Stockholders Equity [Table]
Stockholders Equity [Table]
Stockholders equity table.
Class of Warrant or Right [Axis]
Document Type
Document Type
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Entity Central Index Key
Entity Central Index Key
Debt Securities, Available-for-Sale [Table Text Block]
Summary of Cash Equivalents and Marketable Securities Classified as Available For Sale Securities
Investments, Debt and Equity Securities [Abstract]
Crysvita
Crysvita [Member]
Crysvita.
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Net (decrease) increase in cash, cash equivalents and restricted cash
Subsequent Event Type [Domain]
Common stock equivalents excluded from computation of diluted net loss per share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Common Stock, Par or Stated Value Per Share
Common stock, par value
Issuance of equity from noncontrolling interest
Noncontrolling Interest, Increase from Subsidiary Equity Issuance
Stock issued during period value at market offering.
Stock Issued During Period Value At Market Offering
Issuance of common stock in connection with at-the-market offering, net
Debt Securities, Available-for-Sale, Amortized Cost
Amortized Cost
Amortized Cost
Restructuring and Related Activities, Completion Date
Restructuring and related activities, Completion date
Debt Securities, Available-for-sale, Total
Debt Securities, Available-for-Sale
Estimated Fair Value
Royalty Start Date
Royalty start date.
Royalty start date
Investment [Text Block]
Investment in Amlogenyx Inc.
Open Market Sale
Open Market Sale [Member]
Open market sale.
Solid and Arcturus.
Solid and Arcturus [Member]
Solid and Arcturus
License and Collaboration Agreement
License And Collaboration Agreement [Member]
License and collaboration agreement.
Total accrued liabilities
Accrued liabilities
Accrued Liabilities, Current
Cost of Sales [Member]
Cost of sales
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Current Fiscal Year End Date
Current Fiscal Year End Date
Dojolvi
Dojolvi [Member]
Dojolvi.
Document Quarterly Report
Document Quarterly Report
Accounts payable, accrued, and other liabilities
Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities
Increase decrease in accounts payable accrued liabilities and other operating liabilities.
Entity Address, State or Province
Entity Address, State or Province
Non cash royalty revenue.
Non Cash Royalty Revenue
Non-cash royalty revenue
Investment Owned, Balance, Shares
Shares received
Preferred Stock, Shares Outstanding, Ending Balance
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred stock, shares outstanding
Preferred Stock, Shares Outstanding
Total comprehensive loss
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Gross Unrealized Gains
Cost Sharing Payments [Line Items]
Cost Sharing Payments [Line Items]
Cost sharing payments line items.
Class of Warrant or Right [Domain]
Geographical
Geographical [Axis]
Summary of Stock-Based Compensation Expense
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Research and Clinical Study Expenses
Research and clinical study expenses.
Research and clinical study expenses
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Other comprehensive income (loss):
Other Comprehensive Income, Net of Tax [Abstract]
Performance Shares [Member]
Performance Shares [Member]
Liabilities for sales of future royalties.
Liabilities for Sales of Future Royalties [Table]
Subsequent Event [Member]
Subsequent Event [Member]
Property, Plant and Equipment [Abstract]
Other Assets, Noncurrent
Other assets
Collaboration Payables
Collaboration Payables
Collaboration payables
Debt Securities, Available-for-sale, Current, Total
Debt Securities, Available-for-Sale, Current
Marketable securities
Antidilutive Securities
Antidilutive Securities [Axis]
EMEA [Member]
Europe, Middle East, and Africa
Contract execution date
Contract Execution Date
Contract execution date.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]
Proceeds from Sale of Debt Securities, Available-for-Sale
Proceeds from sale of marketable securities
Royalty Purchase Agreement
Royalty Purchase Agreement [Member]
Royalty purchase agreement.
Arcturus
Arcturus
Arcturus Research Collaboration And License Agreement [Member]
Arcturus research collaboration and license agreement.
Accumulated Other Comprehensive Income (Loss)
AOCI Attributable to Parent [Member]
Customer [Domain]
Treasury Stock, Common, Shares
Treasury stock , shares
Deferred Employee Stock Ownership Plan, Issuance of Shares or Sale of Treasury Shares
Deferred compensation obligation
Preferred Stock, Value, Issued, Total
Preferred Stock, Value, Issued, Ending Balance
Preferred Stock, Value, Issued, Beginning Balance
Preferred Stock, Value, Issued
Preferred stock, par value of $0.001 per share - 25.0 shares authorized; nil outstanding in 2026 and in 2025
Selling, General and Administrative Expense, Total
Selling, general and administrative
Selling, General and Administrative Expense
Minimum
Minimum [Member]
Financial Instrument [Axis]
Employment Inducement Plan
Employment Inducement Plan [Member]
Employment inducement plan.
Current assets:
Assets, Current [Abstract]
Annual license fee payment
Annual License Fee Payment
Annual license fee payment
Fair Value, Inputs, Level 3 [Member]
Level 3
Payment From Sale Of Future Royalties
Payment from sale of future royalties
Payment From Sale Of Future Royalties.
Summary of Financial Assets Measured on Recurring Basis
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
Current liabilities:
Liabilities, Current [Abstract]
Product sales
Product [Member]
Product Revenue
Restructuring and Related Activities Disclosure [Text Block]
Strategic Restructuring Plan
Related Party Transactions [Abstract]
Accounts Receivable, after Allowance for Credit Loss, Current, Total
Accounts receivable, net
Accounts Receivable, after Allowance for Credit Loss, Current
Deferred Compensation, Share-Based Payments [Member]
Deferred Compensation Obligation
Work-in-process
Inventory, Work in Process, Gross
General and Administrative Expense [Member]
Selling, general and administrative
Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]
Restructuring
Prepaid expenses and other assets
Increase (Decrease) in Prepaid Expenses, Other
Prepaid expenses and other assets
Restricted Cash, Current
Restricted cash included in other current assets
Available-for-sale securities remaining contractual maturities
Available For Sale Securities Contractual Maturity
Available for sale securities contractual maturity.
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total
Effect of exchange rate changes on cash
Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]
Summary of restructuring charges and amounts paid or settled
Weighted Average Number of Shares Outstanding, Basic, Total
Weighted Average Number of Shares Outstanding, Basic
Shares used in computing net loss per share, Basic
Percentage of right to receive royalty payments on net sales
Percentage of right to receive royalty payments on net sales.
Royalty Revenue in European Territory
European Union And Switzerland And Turkey [Member]
European Union and Switzerland and Turkey.
Royalty Revenue in European Territories
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total
Shares granted
Subsequent Events
Subsequent Events [Text Block]
APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total
Stock-based compensation
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Beginning balance
Ending balance
Equity, Attributable to Parent
Total stockholders' deficit
Preferred Stock, Par or Stated Value Per Share
Preferred stock, par value
Non cash royalty.
Non Cash Royalty [Member]
Non-cash royalty revenue
Basis of Presentation
Basis of Accounting, Policy [Policy Text Block]
Statement of Stockholders' Equity [Abstract]
Royalty agreement termination threshold amount
Royalty Agreement Termination Threshold Amount
Royalty agreement termination threshold amount.
Collaboration.
Collaboration [Member]
Collaboration Revenue
Type of Restructuring [Domain]
Use of Estimates
Use of Estimates, Policy [Policy Text Block]
Credit Losses
Credit Loss, Financial Instrument [Policy Text Block]
Treasury Stock, Common [Member]
Treasury Stock
Deferred compensation liabilities.
Deferred Compensation Liabilities [Member]
Deferred Compensation Liabilities
Estimated fair value
Investment Owned, Fair Value, Beginning Balance
Investment Owned, Fair Value, Ending Balance
Investment Owned, Fair Value
United States of America
UNITED STATES
Schedule of Accrued Liabilities [Table Text Block]
Summary of Accrued Liabilities
Clinical Milestone Aggregate
Clinical Milestone Aggregate
Clinical Milestone Aggregate
Manufacturing and related expenses
Manufacturing and Related Expenses
Manufacturing and related expenses.
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]
Amlogenyx inc.
Amlogenyx Inc [Member]
Amlogenyx Inc [Member]
Plan Name
Plan Name [Domain]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Entity
Entity [Domain]
Noncontrolling interest
Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Total
Temporary Equity, Including Noncontrolling Interest
Ending Balance
Beginning Balance
Mepsevii.
Mepsevii
Mepsevii [Member]
Royalty Purchase Agreement CAP Aggregate Payment
Royalty purchase agreement cap aggregate payment.
Royalty purchase agreement cap aggregate payment
Schedule of Investments [Line Items]
Percentage of gross accounts receivable balance from different customer
Percentage Of Gross Accounts Receivables From Different Customer
Percentage of gross accounts receivables from different customer.
Rule 10b51 Arr Modified [Flag]
Rule 10b51 arrangement modified.
Rule 10b5-1 Arrangement Modified
Treasury Stock, Value, Total
Treasury Stock, Value
Treasury stock, at cost, 0.3 shares in 2026 and 0.2 shares in 2025
Research and development
Collaborative Arrangements Effective Reduction Of Expense In Research And Development Expenses
Collaborative arrangements effective reduction of expense in research and development expenses.
Offset to research and development expense
Profit Share Territory
United States And Canada [Member]
United States and Canada.
Option to sell common stock aggregate offering price
Option To Sell Common Stock Aggregate Offering Price
Option to sell common stock aggregate offering price.
Related Party
Related and Nonrelated Parties [Axis]
Entity Address, City or Town
Entity Address, City or Town
Number of reportable segments
Number of Reportable Segments
Security Exchange Name
Security Exchange Name
Non controlling Interest in Changes and Adjustments
Changes and adjustments related to noncontrolling Interest.
Changes and adjustments
Liabilities for sales of future royalties.
Liabilities for Sales of Future Royalties [Text Block]
Liabilities for Sales of Future Royalties
Investments, All Other Investments [Abstract]
2023 Incentive Plan
Two Thousand Twenty Three Incentive Plan Member
Two thousand twenty three incentive plan.
Counterparty Name
Counterparty Name [Axis]
Loss before income taxes
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Antidilutive Securities, Name
Antidilutive Securities, Name [Domain]
Investment Owned, Cost
Contributed by affiliated entities
Regeneron pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc [Member]
Regeneron Pharmaceuticals Inc
Total inventory
Inventory
Inventory, Net
GeneTx [Member]
GeneTx [Member]
GeneTx [Member]
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Statistical Measurement
Statistical Measurement [Domain]
Deferred compensation.
Deferred Compensation
Deferred compensation
Total current assets
Assets, Current
Stock-based compensation expense
Share-Based Payment Arrangement, Expense
Document Period End Date
Document Period End Date
Fair Value Hierarchy and NAV [Domain]
Foreign currency translation adjustments
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax
Statement of Financial Position [Abstract]
Restricted Stock Units (RSUs) [Member]
Restricted Stock Units (RSUs) [Member]
License and Research Agreements
Collaborative Arrangement And Noncollaborative Arrangement Transactions Disclosure [Text Block]
Collaborative arrangement and noncollaborative arrangement transactions disclosure.
Revenue Recognition
Revenue [Policy Text Block]
R P I Finance Trust Two Thousand Nineteen [Member]
RPI finance trust two thousand nineteen.
RPI Finance Trust 2019
Two Thousand Twenty Four Equity Incentive Plan [Member]
Two Thousand Twenty Four Equity Incentive Plan [Member]
2024 Equity Incentive Plan [Member]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Antidilutive Security, Excluded EPS Calculation [Table]
Class of Stock [Axis]
License agreement other receivables
Other Receivables
Commercial Paper
Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Total liabilities
Liabilities
Pre-funded Warrants And Stock Issued During Period Shares At Underwritten Public Offering
Pre-funded warrants and stock issued during period shares at underwritten public offering.
Issuance of common stock and pre-funded warrants in connection with the underwritten public offering, net, shares
Financial Instruments [Domain]
Cost of sales and operating expenses.
Cost Of Sales And Operating Expenses
Total operating expenses
Investment in Solid Common Stock [Member]
Investment in solid common stock member.
Investment in Solid common stock
Weighted Average Number of Shares Outstanding, Diluted, Total
Weighted Average Number of Shares Outstanding, Diluted
Shares used in computing net loss per share, Diluted
Entity File Number
Securities Act File Number
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax
Change in unrealized loss on available-for-sale securities
Cover [Abstract]
John Pinion [Member]
John Pinion [Member]
John pinion .
Schedule Of Key Terms And Activity Of Sales Of Future Royalties [Table Text Block]
Schedule of key terms and activity of sales of future royalties.
Schedule of Key Terms and Activity of Sales of Future Royalties
Prepaid Expense and Other Assets, Current
Prepaid expenses and other assets
Investments
Investments [Domain]
Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible List]
Restricted Cash and Cash Equivalent, Noncurrent, Statement of Financial Position [Extensible Enumeration]
Balance Sheet Components
Supplemental Balance Sheet Disclosures [Text Block]
Future milestones payable
Future Milestones Payable
Future milestones payable.
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized
Shares authorised for issuance
Share of Collaboration and Royalty Revenue Related to Crysvita
Schedule Of Collaboration And Royalty Revenue Table [Text Block]
Schedule of collaboration and royalty revenue.
Sale of Stock
Sale of Stock [Domain]
Options to purchase common stock, restricted stock units and performance stock units.
Options To Purchase Common Stock Restricted Stock Units And Performance Stock Units [Member]
Options to Purchase Common Stock, RSUs, and PSUs
Options to Purchase Common Stock, RSUs, and PSUs
Share repurchase expiration date
Share Repurchase Program, Expiration Date
Balance of contract liabilities at beginning of period
Contract with customer assets (liability) current.
Contract With Customer Assets Liability Current
Balance of contract liabilities at beginning of period
Balance of contract liabilities at end of period, net
Stock issued during period shares at market offering.
Issuance of common stock in connection with at-the-market offering, net, shares
Stock Issued During Period Shares At Market Offering
Restructuring Charges
Restructuring Charges, Total
Restructuring charges
New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Emplooyee-Related
Employee Severance [Member]
Accumulated Other Comprehensive Loss
Comprehensive Income (Loss) Note [Text Block]
Common stock, shares outstanding
Beginning balance, shares
Ending balance, shares
Common Stock, Shares, Outstanding
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Depreciation, Depletion and Amortization, Total
Depreciation and amortization
Depreciation, Depletion and Amortization
Document Transition Report
Document Transition Report
Research and Development Expense, Total
Research and development
Research and Development Expense
Organization And Nature Of Business [Table]
Organization And Nature Of Business [Table]
Organization and nature of business.
Solid Biosciences Inc [Member]
Solid Biosciences, Inc.
Solid Biosciences Inc [Member]
Statement of Cash Flows [Abstract]
Future contingent milestone payments
Future Contingent Milestone Payments
Future contingent milestone payments.
Equity [Text Block]
Equity
Net Loss Per Share
Earnings Per Share [Text Block]
Royalties Agreement Territories
Royalties agreement territories.
Royalties agreement territories
Net loss
Net loss
Increase (Decrease) in Inventories, Total
Inventory
Increase (Decrease) in Inventories
Customer Two.
Customer Two [Member]
Customer Two
Royalty Contract Execution Date
Royalty contract execution date.
Contract execution date
Intangible Assets, Net (Excluding Goodwill), Total
Intangible assets, net
Intangible Assets, Net (Excluding Goodwill)
Liabilities for sales of future royalties current
Liabilities for Sales of Future Royalties Current
Liabilities for sales of future royalties
Assets
Assets [Abstract]
Restructuring and Related Activities [Abstract]
Document Fiscal Year Focus
Document Fiscal Year Focus
Asia Pacific [Member]
Asia-Pacific
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
Schedule of Total Accumulated Other Comprehensive Loss
Investing activities:
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]
Accounts Payable, Current, Total
Accounts payable
Accounts Payable, Current
Research and development
Research and Development Expense [Member]
Kyowa Kirin Collaboration [Member]
Kyowa Kirin Collaboration.
Kyowa Kirin Collaboration [Member]
Kyowa Kirin Collaboration
Restructuring Cost and Reserve [Line Items]
Fair Value Disclosures [Abstract]
Royalty Purchase Agreement CAP Amount
royalty purchase agreement cap amount.
Royalty purchase agreement cap amount
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Loss, Net of Tax [Abstract]
North America
North America [Member]
Regulatory milestone payments achieved.
RegulatoryMilestonePaymentsAchieved
Regulatory milestone payments achieved
Liability for sale of future royalties at end of year
Liability For Sale Of Future Royalties
Liability for sale of future royalties.
Liability for sale of future royalties at beginning of year
Share-Based Payment Arrangement [Abstract]
Cost of sales
Cost Of Sales
Cost of sales.
Liability for sale of future royalties.
Liability For Sale Of Future Royalties [Line Items]
Sale of Stock
Sale of Stock [Axis]
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Net cash (used in) provided by investing activities
Two Thousand Twenty Two OMERS Agreement [Member]
Two thousand twenty two OMERS agreement.
2022 OMERS Agreement
Title of 12(b) Security
Title of 12(b) Security
Agreement counterparty
Royalty Agreement Counterparty Name
Royalty agreement counterparty name.
Money Market Funds
Money Market Funds [Member]
Related Party
Related and Nonrelated Parties [Domain]
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Amended and restated two thousand fourteen employee stock purchase plan.
Amended and Restated Two Thousand Fourteen Employee Stock Purchase Plan [Member]
Amended & Restated 2014 Employee Stock Purchase Plan
Eligible future milestone payments
Eligible future milestone payments.
Eligible Future Milestone Payments
Liability Related To Sale Of Future Royalties
Liability related to sale of future royalties.
Liabilities related to the sale of future royalties at beginning of year
Liabilities related to the sale of future royalties at end of year
Liabilities for sales of future royalties
Other liabilities
Other Liabilities, Noncurrent, Total
Other Liabilities, Noncurrent
Legal Entity
Legal Entity [Axis]
Changes in operating assets and liabilities:
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]
Contract with customer liability deductions during period.
Contract With Customer Liability Deductions During Period
Deductions
Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised
Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised, Total
Proceeds from the issuance of common stock under equity plans, net
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Fair Value, Recurring and Nonrecurring [Table]
Additional Paid-in Capital
Additional Paid-in Capital [Member]
Income Statement Location
Statement of Income Location, Balance [Axis]
Trading Symbol
Trading Symbol
Related Party Transaction [Table]
Royalties Earned From Inception
Royalties Earned From Inception.
Subsequent Event Type [Axis]
Stock-based compensation
Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost
Allocated share based compensation expense net of capitalized inventory cost.
Employee-related Liabilities, Current, Total
Payroll and related expenses
Employee-related Liabilities, Current
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]
Financing activities:
Proceeds From Issuance Of Common Stock At Market Offering
Proceeds from issuance of common stock at market offering.
Net proceeds from at-the-market offering
Proceeds from the issuance of common stock in connection with at-the-market offering, net
Equity Components
Equity Components [Axis]
Equity Component
Equity Component [Domain]
Asset Class
Asset Class [Axis]
Business Combination [Axis]
Issuance of common stock under equity plan awards, net of tax, shares
Issuance Of Common Stock Under Equity Plan Awards Net Of Tax Shares
Issuance of common stock under equity plan awards, net of tax, shares.
Profit loss sharing percentage on net sales
Profit Loss Sharing Percentage On Net Sales
Profit loss sharing percentage on net sales.
Customer [Axis]
Organization And Nature Of Business [Line Items]
Organization And Nature Of Business [Line Items]
Organization and nature of business.
Statement of Comprehensive Income [Abstract]
Maximum
Maximum [Member]
Statistical Measurement
Statistical Measurement [Axis]
Common Stock, Value, Issued, Ending Balance
Common Stock, Value, Issued, Beginning Balance
Common Stock, Value, Issued, Total
Common stock investment value
Common Stock, Value, Issued
Common stock, par value of $0.001 per share - 250.0 shares authorized; outstanding - 98.6 in 2026 and 96.6 in 2025
Royalty revenue.
Royalty Revenue
Royalty revenue
Royalty revenue
Royalty revenue
Royalty [Member]
Royalty
Percentage of royalty on net sales receives
Royalty Percentage On Net Sales
Royalty percentage on net sales.
Accrued Liabilities, Total
License agreement accrued liabilities
Accrued Liabilities
Schedule of Cost Sharing Payments
Schedule Of Cost Sharing Payments Table [Text Block]
Schedule of cost sharing payments.
Rule 10b51 Plan One [Member]
Rule 10b51 plan one.
Plan 1
Preferred stock, shares authorized
Preferred Stock, Shares Authorized
Royalty Repurchase Option Description
Royalty Repurchase Option Description.
Royalty repurchase option description
At the Market Offering [Member]
At-the-market offering.
At-the-Market Offerings
Manufacturing Facility [Member]
Manufacturing Related
Related Party Transaction [Line Items]
Revenue
Revenue from Contract with Customer [Text Block]
Entity Registrant Name
Entity Registrant Name
Underwritten Public Offering
Underwritten Public Offering [Member]
Underwritten public offering.
Howard Horn [Member]
Howard horn.
Howard Horn [Member]
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Gross Unrealized Losses
Evkeeza.
Evkeeza [Member]
Evkeeza
Non-cash interest expense
Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
Non cash interest expense on liability related to sale of future royalties.
Non-cash interest expense on liabilities for sales of future royalties
Non-cash interest expense on liabilities for sales of future royalties
Other Nonoperating Income (Expense)
Other Nonoperating Income (Expense), Total
Other income
Additional Paid in Capital, Ending Balance
Additional Paid in Capital, Beginning Balance
Additional Paid in Capital, Total
Additional paid-in capital
Additional Paid in Capital
Subsequent Events [Abstract]
Income Tax Expense (Benefit), Total
Provision for income taxes
Income Tax Expense (Benefit)
Accrued collaboration payables.
AccruedCollaborationPayables
Accrued collaboration payables
Cost Sharing Payments [Abstract]
Cost sharing payments abstract.
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Upfront payments of collaboration.
Upfront Payments of Collaboration
Upfront payments of collaboration
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Accumulated Other Comprehensive Income (Loss), Net of Tax
Total accumulated other comprehensive loss
Accumulated other comprehensive loss
Accounts Receivable, Allowance for Credit Loss, Writeoff
Credit losses recorded for receivables
Payments for Restructuring
Cash settled
Cash settled/ adjustment
Payments to Acquire Property, Plant, and Equipment, Total
Purchase of property, plant, and equipment
Payments to Acquire Property, Plant, and Equipment
Other
Other
Payment for (Proceeds from) Other Investing Activity
Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash
Restrictions on Cash and Cash Equivalents [Table Text Block]
Total assets
Assets
Total assets
Income Statement [Abstract]
Restructuring Cost [Table]
Selling, general and administrative
Selling, General and Administrative Expenses [Member]
Common stock shares sold
Stock Issued During Period, Shares, New Issues
Consolidation, Variable Interest Entity, Policy [Policy Text Block]
Variable Interest Entity, Policy
Earnings Per Share, Diluted, Total
Earnings Per Share, Diluted
Net loss per share, diluted
Disaggregation of Revenue [Abstract]
City Area Code
City Area Code
Research Grant Agreement [Abstract]
Research grant agreement.
Other Comprehensive Income (Loss), Net of Tax
Other comprehensive income (loss):
Other comprehensive income (loss)
Issuance of common stock and pre-funded warrants in connection with the underwritten public offering, net
Pre-funded Warrants And Stock Issued During Period Value At Underwritten Public Offering
Pre-funded warrants and stock issued during period value at underwritten public offering.
Stockholders Equity [Line Items]
Stockholders Equity [Line Items]
Stockholders equity line items.
Collaboration And Royalty [Member]
Collaboration and Royalty
Collaboration and royalty.
Contract with customer liability additions during period.
Contract With Customer Liability Additions During Period
Additions
Counterparty Name
Counterparty Name [Domain]
Investor [Member]
Third-Party Investor [Member]
License Agreement
License Agreement Terms [Member]
Deferred Revenue Disclosure [Abstract]
Property, Plant and Equipment, Net, Ending Balance
Property, Plant and Equipment, Net, Beginning Balance
Property, Plant and Equipment, Net, Total
Property, plant, and equipment, net
Property, Plant and Equipment, Net
Total cash, cash equivalents, and restricted cash shown in the statements of cash flows
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Corporate Bonds
Corporate Bond Securities
Corporate Bond Securities [Member]
Loss from operations
Operating Income (Loss)
Accumulated Deficit
Retained Earnings [Member]
Related Party Payment of Contribution
Related Party Payment of Contribution
Contribution amount paid
Mereo
Mereo Bio Pharma3 Limited [Member]
Mereo BioPharma 3 Limited.
Fair Value, Inputs, Level 1 [Member]
Level 1
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Net cash provided by financing activities
Daiichi Sankyo
Daiichi Sankyo Co Ltd [Member]
Daiichi Sankyo Co., Ltd.
Deferred Income Tax Liabilities, Net, Total
Deferred tax liabilities
Deferred Income Tax Liabilities, Net
Common stock, Beginning balance
Investments, Fair Value Disclosure, Total
Total fair value
Common stock, Ending balance
Investments, Fair Value Disclosure
Licenses Agreement.
License Agreement
Licenses Agreement [Member]
Cost Sharing Payments [Table]
Cost Sharing Payments [Table]
Cost sharing payments table.
AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax, Total
AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax
Unrealized loss on available-for-sale securities
Outstanding Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Debt Securities Available For Sale [Table]
Debt Securities, Available-for-Sale [Table]
Entity Interactive Data Current
Entity Interactive Data Current
Income Statement Location
Statement of Income Location, Balance [Domain]
Payments made under agreement.
Payments made under agreement
Payments Made Under Agreement
RPI Finance Trust (RPI)
R P I Finance Trust [Member]
RPI Finance Trust.
Operating activities:
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]
Common Stock Shares Issued Not Disclosed
Common stock shares issued not disclosed.
Accretion (Amortization) of Discounts and Premiums, Investments
Amortization of discount on marketable securities, net
Amortization of discount on marketable securities, net
Entity Tax Identification Number
Entity Tax Identification Number
Revenues:
Revenues [Abstract]
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale
Proceeds from maturities of marketable securities
Redeemable Noncontrolling Interest [Table Text Block]
Changes in the Carrying Value of Noncontrolling Interest
Local Phone Number
Local Phone Number
U.S. Government Treasury and Agency Securities
U S Government Treasury And Agency Securities [Member]
United states government treasury and agency securities.
Other Liabilities, Current
Other liabilities
Schedule of Changes in Fair Value of Investment in Securities
Schedule Of Changes In Fair Value Of Investment In Securities Table [Text Block]
Schedule of changes in fair value of investment in securities.
Restructuring Costs
Restructuring Costs, Total
Restructuring expense
Total restructuring expense
Customer Three [Member]
Customer three.
Customer Three
Accounting Policies [Abstract]
Disaggregation Of Revenue [Line Items]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax, Total
Total revenues
Revenue from Contract with Customer, Excluding Assessed Tax
Collaboration and license revenue
Proceeds from the sale of future royalties, net
Proceeds From Royalties Received Financing Activities
Proceeds from royalties received financing activities.
Net proceeds from sale of future royalties
Inventory, Net [Abstract]
Class of Stock [Domain]
Share reserved for future issuance
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant
Restricted Cash and Cash Equivalents, Current, Asset, Statement of Financial Position [Extensible List]
Restricted Cash and Cash Equivalent, Current, Statement of Financial Position [Extensible Enumeration]
Entity Emerging Growth Company
Entity Emerging Growth Company